Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT03525054
Recruiting Observational

Semantic and Syntactic Computerized Analysis of Free Speech

NCT03525054 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2018-05-18
Last updated
2026-06-02

Condition(s) studied

Psychotic DisordersPsychosisSchizophrenia and Related DisordersSchizophrenia ProdromalDiagnosis, Psychiatric

Study summary

Subtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify specific linguistic markers of the psychotic transition to validate a french predictive model of this transition using computerized speech analysis techniques

Eligibility

Sex
ALL
Min age
15 Years
Max age
30 Years
Healthy volunteers
No
Inclusion Criteria: * Major and/or minor from 15 to 30 years old * Who alleged a suicidal gesture or idea or behavior that has repercussions in their emotional, social or professional life * If patients receive neuroleptic treatment that impairs cognitive abilities, a one-week wash-out period will be scheduled prior to assessment. * Affiliated with or beneficiary of a health insurance/social security system * Able and willing to provide written informed consent Exclusion Criteria: * History of psychosis * Risk of self-harm or violence not compatible with outpatient treatment * QI\<70 (WAIS) * Neurological disorder or major health problem * Impossibility to interrupt neuroleptic treatment for one week * Refusal to participate

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
CHRU de Brest Brest France Recruiting
Meunier Sophie Caen France Not Yet Recruiting
CH de SAINT ANNE Paris France Recruiting

More University Hospital, Brest trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03525054 on ClinicalTrials.gov ↗ ← All trials in France